ANMI SA develops radiopharmaceuticals labeled with radiometals, focusing on the scalable synthesis of theranostic agents for nuclear medicine. The company enhances patient access to these specialized treatments by streamlining production processes in hospitals and radiopharmacies.
Funding
Funding not disclosed
Founders
Product
Problem
The production of radiopharmaceuticals, particularly those labeled with radiometals for theranostic applications, often faces challenges in scalability and cost-effectiveness, hindering widespread access for patients who could benefit from these specialized treatments. Current synthesis methods can be complex and difficult to implement in hospital and radiopharmacy settings.
Solution
ANMI SA develops innovative radiopharmaceutical solutions focused on streamlining the synthesis of theranostic agents labeled with radiometals. By optimizing production processes, ANMI aims to enhance the accessibility of these advanced nuclear medicine treatments for a broader patient population. Their solutions are designed to facilitate scalable and cost-effective production within hospital and radiopharmacy environments, simplifying the daily workflow for medical professionals. This approach ensures that more patients can receive timely and effective theranostic care.
Target Audience
ANMI SA primarily targets hospitals and radiopharmacies involved in nuclear medicine, as well as medical professionals seeking to improve patient access to theranostic radiopharmaceuticals.
Features
- Development of radiopharmaceutical solutions for theranostic applications.
- Focus on radiometal-labeled compounds.
- Streamlined synthesis processes for ease of use in hospitals and radiopharmacies.
- Scalable production methods to increase availability of theranostic agents.
- Cost-effective solutions to reduce the financial burden of radiopharmaceutical production.